Consumer group petitions FDA to pull generic antifungal med

Currently, there are several generics on the U.S. market of oral antifungal agent ketoconazole. But consumer advocacy organization Public Citizen is trying to change that. On Tuesday, it petitioned the FDA to pull them from the market, claiming the med's risks of fatal liver failure and adrenal insufficiency--as well as its "numerous drug interactions"--outweigh benefits it deemed "limited." Petition (PDF)

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.